VERA
Vera Therapeutics Inc
NASDAQ: VERA · HEALTHCARE · BIOTECHNOLOGY
$35.84
-3.42% today
Updated 2026-04-29
Market cap
$2.57B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-4.66
Dividend yield
—
52W range
$19 – $56
Volume
1.2M
Vera Therapeutics Inc (VERA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.86M | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | -100.0% | — |
| Cost of revenue | $509000.00 | $251000.00 | $176000.00 | $-846000.00 | $-1.86M | $2.17M | $468000.00 |
| Gross profit | $-509000.00 | $-251000.00 | $-176000.00 | $846000.00 | $1.86M | $-2.17M | $-468000.00 |
| Gross margin | — | — | — | — | 100.0% | — | — |
| R&D | $7.29M | $43.92M | $22.48M | $68.99M | $78.22M | $126.17M | $215.26M |
| SG&A | $4.41M | $4.04M | $11.92M | $21.91M | $23.79M | $41.00M | $100.22M |
| Operating income | $-11.96M | $-48.06M | $-34.40M | $-90.90M | $-102.01M | $-167.17M | $-315.47M |
| Operating margin | — | — | — | — | -5478.6% | — | — |
| EBITDA | $-11.29M | $-52.99M | $-34.23M | $-91.75M | $-92.18M | $-144.42M | $-291.62M |
| EBITDA margin | — | — | — | — | -4950.7% | — | — |
| EBIT | $-11.80M | $-53.25M | $-34.40M | $-90.90M | $-92.20M | $-144.52M | $-292.08M |
| Interest expense | $51000.00 | $166000.00 | $20000.00 | $992000.00 | $3.79M | $7.63M | $7.53M |
| Income tax | $1000.00 | $1000.00 | $1000.00 | $1000.00 | $1000.00 | $1000.00 | — |
| Effective tax rate | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | 0.0% |
| Net income | $-11.85M | $-53.41M | $-32.61M | $-89.06M | $-95.99M | $-152.15M | $-299.62M |
| Net income growth (YoY) | — | -350.6% | +38.9% | -173.1% | -7.8% | -58.5% | -96.9% |
| Profit margin | — | — | — | — | -5155.2% | — | — |